Emmaus Life Sciences Inc (OTCQX:EMMA) said it has obtained marketing authorization from the Puerto Rico Department of Health for its sickle cell disease (SCD) treatment, Endari, an L-glutamine oral powder.
This approval enhances accessibility to Endari for SCD patients in Puerto Rico, addressing challenges in accessing innovative treatments.
Endari is already approved in the United States, Israel, United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman.
As the first FDA-approved oral glutamine therapy, Endari has demonstrated efficacy in reducing the frequency of pain crises, hospitalizations, and other acute complications in both adult and pediatric SCD patients.
"We are thrilled to bring Endari to Puerto Rico, where the SCD community has faced significant challenges in accessing innovative treatments," said George Sekulich, co-president of Emmaus Life Sciences.
"This approval is a testament to our commitment to working with regulatory authorities and patient advocacy groups to expand access to Endari for all who need it."